Expertise and rankings

Image shows members of the pancreatic cancer team discussing a patient

Mayo Clinic doctors conduct research to advance the diagnosis and treatment of bile duct cancer.

Mayo Clinic doctors have extensive experience diagnosing and treating many people with cholangiocarcinoma, an uncommon type of cancer. They treat more than 305 people with bile duct and gallbladder cancers each year. And Mayo Clinic is one of the major referral centers in the United States for primary sclerosing cholangitis, which is the major risk factor for bile duct cancer.

Mayo Clinic surgeons pioneered the use of liver transplant to treat hilar cholangiocarcinoma. They have performed many liver transplant procedures and other surgical procedures to treat bile duct cancers. Extensive research shows that surgeries result in fewer complications when done by highly experienced surgeons at centers that do many of these operations.

Mayo Clinic Cancer Center meets strict standards for a National Cancer Institute comprehensive cancer center, which recognizes scientific excellence and a multidisciplinary approach to cancer prevention, diagnosis and treatment.

Mayo Clinic in Rochester, Minn., Mayo Clinic in Jacksonville, Fla., and Mayo Clinic in Scottsdale, Ariz., are ranked among the Best Hospitals for cancer by U.S. News & World Report.

Mayo Clinic in Rochester, Minn., ranks No. 1 for digestive disorders in the U.S. News & World Report Best Hospitals rankings. Mayo Clinic in Scottsdale, Ariz., and Mayo Clinic in Jacksonville, Fla., are ranked among the Best Hospitals for digestive disorders by U.S. News & World Report. Mayo Clinic also ranks among the Best Children's Hospitals for digestive disorders.

Learn more about Mayo Clinic's quality rankings.

April 25, 2017
References
  1. AskMayoExpert. Cholangiocarcinoma. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2016.
  2. Feldman M, et al. Tumors of the bile ducts, gallbladder and ampulla. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 10th ed. Philadelphia, Pa.: Saunders Elsevier; 2016. http://www.clinicalkey.com. Accessed Feb. 22, 2016.
  3. Rizvi S, et al. Current diagnostic and management options in perihilar cholangiocarcinoma. Digestion. 2014;89:216.
  4. Zaydfudim VM, et al. Hilar cholangiocarcinoma. Surgical Oncology Clinics of North America. 2014;23:247.
  5. Riggin EA. Allscipts EPSi. Mayo Clinic, Rochester, Minn. Oct. 27, 2016.
  6. Brown AY. Allscripts EPSi. Mayo Clinic, Rochester, Minn. Nov. 3, 2016.
  7. Smoot RL (expert opinion). Mayo Clinic, Rochester, Minn. March 23, 2017.
  8. Choi J, et al. Aspirin use and the risk of cholangiocarcinoma. Hepatology. 2016;64:785.
  9. Doherty B, et al. Update on the diagnosis and treatment of cholangiocarcinoma. Current Gastroenterology Reports. 2017;19:2.
  10. Borad MJ, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PloS Genetics 2014;10:e1004135. http://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1004135. Accessed Feb. 27, 2017.
  11. Barbara Woodward Lips Patient Education Center. Surgery on the extrahepatic bile duct, duodenum, papilla, or pancreas. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2012.
  12. Merck Manual Professional Version. Tumors of the gallbladder and bile ducts. https://www.merckmanuals.com/professional/hepatic-and-biliary-disorders/gallbladder-and-bile-duct-disorders/tumors-of-the-gallbladder-and-bile-ducts#v902250. Accessed Feb. 28, 2017.
  13. Bergquist JR, et al. Implications of CA19-9 elevation for survival, staging and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis. Journal of Surgical Oncology. 2016;114:475.